Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human GPR35 Stable Cell Line

    [CAT#: S01YF-0923-PY165]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    GPCR Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Protein
    GPR35
    Target Family
    Orphan Family
    Target Protein Species
    Human
    Host Cell Type
    LS174T;CHO-K1;HEK293
    Target Classification
    GPCR Cell Lines
    Target Research Area
    CNS Research;Digestive and Renal Research
    Related Diseases
    Cholangitis, Primary Sclerosing;Microphthalmia, Isolated 1.
    Gene ID
    Human: 2859
    UniProt ID
    Human: Q9HC97

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    GPR35 has been identified as a receptor that plays a role in various physiological processes. It promotes neutrophil recruitment in response to the serotonin metabolite 5-HIAA. Additionally, GPR35 activation has been linked to angiogenesis in the tumor microenvironment. This receptor's structural insights have also been explored, revealing its unique ligand recognition mode and potential as a therapeutic target.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human GPR35 Stable Cell Line (S01YF-0923-PY165). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Jennifer (Verified Customer)

    How does GPR35 expression impact lipid metabolism in hepatocyte cell lines? Apr 27 2023

    chat Patrick Liam (Creative Biolabs Scientific Support)

    In hepatocyte cell lines, GPR35 expression has been shown to suppress lipid accumulation, which can be critical in studying and understanding metabolic disorders and potential treatments​​. Apr 27 2023

    chat Jason (Verified Customer)

    Are there known ligands for GPR35 that affect its activity in cell lines? Dec 17 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    Yes, GPR35 has been shown to be activated by metabolites such as tryptophan-derived kynurenic acid (KYNA), chemokine CXCL17, and phospholipid derivate lysophosphatidic acid (LPA) species, which could be studied further using stable cell lines expressing GPR35​​. Dec 17 2022

    Published Data

    Fig.1 The suppression of GPR35 resulted in a reduction of the suppressive impact of CID-2745687 on the activity of YAP/TAZ, thus demonstrating the intricate interplay between these factors.

    The researchers investigated the impact of CID treatment on LS174T cells with and without GPR35 knockdown after a 3-hour exposure. It was observed that YAP phosphorylation levels exhibited a dose-dependent increase in the control group, whereas TAZ expression showed a corresponding decrease following CID treatment. Interestingly, these cellular responses were noticeably attenuated in the LS174T cells with GPR35 knockdown, highlighting the role of GPR35 in modulating CID-induced effects.

    Ref: Otkur, Wuxiyar, et al. "GPR35 antagonist CID-2745687 attenuates anchorage-independent cell growth by inhibiting YAP/TAZ activity in colorectal cancer cells." Frontiers in Pharmacology 14 (2023): 1126119.

    Pubmed: 37113762

    DOI: 10.3389/fphar.2023.1126119

    Research Highlights

    Li T, et al. "Fasting-mimicking diet alleviates inflammatory pain by inhibiting neutrophil ." Cell communication and signaling : CCS, 2023.
    Neutrophil Extracellular Traps (NETs) have been found to play a role in promoting neuroinflammation and central nervous system (CNS) disease progression. However, it is still unclear whether CNS-associated NETs have an impact on pain outcomes. Previous studies have shown that a fasting-mimicking diet (FMD) can alleviate neurological disorders by reducing neuroinflammation and promoting nerve regeneration. In this study, the researchers aimed to investigate the effects of NETs in the CNS during acute pain and the role of FMD in inhibiting NETs and relieving pain. To achieve this, the researchers established an inflammatory pain model in mice and employed various methods such as PAD4 siRNA, CI-amidine (PAD4 inhibitor), AAV-GFAP-shRNA, AAV-hSyn-shRNA, and selegiline (MAO-B inhibitor) to inhibit the formation of NETs. They also examined changes in NETs, neuroinflammation, and related signaling pathways through various techniques such as western blot, immunofluorescence, ELISA, and flow cytometry. The results showed that in the acute phase of inflammatory pain, NETs accumulated in the spinal cords of mice, which was associated with increased neuroinflammation. Inhibiting NETs formation was found to alleviate allodynia and neuroinflammation in the mice. FMD was also shown to inhibit NETs production and alleviate inflammatory pain, which was further enhanced by treatment with the NETs inhibitor CI-amidine and reversed by treatment with the NETs inducer phorbol 12-myristate 13-acetate (PMA). The researchers also found that the neutrophil-recruiting pathway MAO-B/5-hydroxyindoleacetic acid (5-HIAA) / G-protein-coupled receptor 35 (GPR35) and NETs-inducing pathway MAO-B/ Reactive oxygen species (ROS) were significantly upregulated during the development of inflammatory pain. Further investigation revealed that MAO-B was largely expressed in astrocytes and neurons in the spinal cords of mice with CFA-induced inflammatory pain. However, inhibiting or knocking down MAO-B was found to effectively attenuate inflammatory pain, NETs formation, and neuroinflammation in the spinal cords. In addition, the researchers performed rescue experiments and found that MAO-B inhibitors synergistically enhanced the pain relief and NETs inhibition induced by FMD
    Pubmed: 37735678   DOI: 10.1186/s12964-023-01258-2

    Nakashima F, et al. "Eriodictyol and thymonin act as GPR35 agonists.." Bioscience, biotechnology, and biochemistry, 2023.
    In this study, the authors aimed to identify potential GPR35 agonists among 19 different herbs and spices in order to understand the mechanisms behind their reported health benefits. Through screening, they found that the ethyl acetate extract of thyme exhibited significant GPR35 agonistic activity. Further analysis revealed that two polyphenolic compounds, eriodictyol and thymonin, were responsible for this activity. Both compounds showed potent and specific agonist activity toward GPR35. These findings suggest that eriodictyol and thymonin may have beneficial health effects through GPR35 activation.
    Pubmed: 37667527   DOI: 10.1093/bbb/zbad125

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare